Drug Profile

Research programme: urea intravitreal - Innovations In Sight

Alternative Names: Glaucoma therapy - Innovations In Sight; Glaucoma therapy - VitreoRetinal; Neurosolve

Latest Information Update: 09 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VitreoRetinal Technologies
Developer Innovations In Sight
Class Radiopharmaceutical diagnostics; Skin disorder therapies; Urea compounds
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinitis pigmentosa

Highest Development Phases

No development reported Glaucoma

Most Recent Events

28 Jul 2018 No recent reports of development identified for preclinical development in Glaucoma in USA (Intravitreous, Injection)
20 Sep 2011 Preclinical development is ongoing in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com